| answer text |
<p>Patients with tuberous sclerosis complex (TSC) have access to standard anti-epileptic
drugs and whilst not licensed specifically for use in association with TSC, there
is evidence that two thirds of patients will respond to treatment. A relatively new
option specifically licensed for refractory epilepsy in TSC is everolimus (Votubia)
which is due to be considered for prioritisation within the National Health Service
in England in December as part of NHS England’s biannual relative prioritisation process
for specialised services.</p><p> </p><p>The life sciences sector deal, published last
autumn, will ensure that the next wave of breakthrough treatments, innovative medical
research and technologies are created in Britain. A key part of the deal was our commitment
to improving patient access to innovation through the implementation of the Accelerated
Access Review.</p>
|
 |
